Abel, B S, Muniyappa, R, Stratton, P, Skarulis, M C, Gorden, P & Brown, R J. (2016). Effects of recombinant human leptin (Metreleptin) on nocturnal luteinizing hormone secretion in lipodystrophy patients. Neuroendocr 103, 402–407.
Ak, M, Sezlev, D, Sutcigil, L, Akarsu, S, Ozgen, F & Yanik, T. (2013). The investigation of leptin and hypothalamic neuropeptides role in first attack psychotic male patients: olanzapine monotherapy. Psychoneuroendocr 38, 341–347.
Alsalim, W, Omar, B, Pacini, G, Bizzotto, R, Mari, A & Ahrén, B. (2015). Incretin and islet hormone responses to meals of increasing size in healthy subjects. J Clin Endocr Metab 100, 561–568.
Angulo, M A, Butler, M G & Cataletto, M E. (2015). Prader-Willi syndrome: a review of clinical, genetic, and endocrine findings. J Endocr Invest 38, 1249–1263.
Arango, C, Rojas, M J, Moreno, D & Parellada, M. (2002). Sibutramine for compulsive eating in hypothalamic deficiency. J Am Acad Child Adolesc Psych 41, 1147–1148.
Astrup, A, Rössner, S, Van Gaal, L et al., on behalf of the NN8022-1807 Study Group. (2009). Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374, 1606–1616.
Bak, M J, Albrechtsen, N J W, Pedersen, J et al. (2014). Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diabetes Obes Metab 16, 1155–1164.
Bakker, N E, Wolffenbuttel, K P, Looijenga, L H & Hokken-Koelega, A C. (2015). Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. J Urol 193, 291–298.
Bakker, N E, Lindberg, A, Heissler, J et al. (2017). Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS Database. J Clin Endocr Metab 102, 1702–1711.
Ballon, J S, Pajvani, U B, Mayer, L E S et al. (2018). Pathophysiology of drug induced weight and metabolic effects: findings from an RCT in healthy volunteers treated with olanzapine, iloperidone, or placebo. J Psychopharmacol 32, 533–540.
Beall, C, Hanna, L & Ellacott, K L J. (2017). CNS targets of adipokines. Compr Physiol 7, 1359–1406.
Benedict, C, Axelsson, T, Söderberg, S et al. (2014). Fat mass and obesity-associated gene (FTO) is linked to higher plasma levels of the hunger hormone ghrelin and lower serum levels of the satiety hormone leptin in older adults. Diabetes 63, 3955–3959.
Bray, G A & Gallagher, T F Jr. (1975). Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a review of the literature. Medicine 54, 301–330.
Brown, R J, Araujo-Vilar, D, Cheung, P T et al. (2016). The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocr Metab 101, 4500–4511.
Carr, R D, Larsen, M O, Jelic, K et al. (2010). Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocr Metab 95, 872–878.
Çetinkaya, S, Güran, T, Kurnaz, E et al. (2018). A patient with proopiomelanocortin deficiency: an increasingly important diagnosis to make. J Clin Res Ped Endocr 10, 68–73.
Chen, K Y, Muniyappa, R, Abel, B S et al. (2015). RM-493, a melanocortin-4 receptor (MC4R) agonist, increases resting energy expenditure in obese individuals. J Clin Endocr Metab 100, 1639–1645.
Chou, S C & Mantzoros, C. (2014). Role of leptin in human reproductive disorders. J Endocr 223, T49–T62.
Colldén, G, Tschöp, M H & Müller, T D. (2017). Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci 18, 798.
Collet, T-H, Dubern, B, Mokrosinski, J et al. (2017). Evaluation of a melanocortin-4 receptor (MC4 R) agonist (Setmelanotide) in MC4 R deficiency. Mol Metab 6, 1321–1329.
Considine, R V, Sinha, M K, Heiman, M L et al. (1996). Serum immunoreactive-leptin concentrations in normal-weight and obese humans. New Eng J Med 334, 292–295.
Cummings, D E, Purnell, J Q, Frayo, R S, Schmidova, K, Wisse, B E & Weigle, D S. (2001). A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719.
Currow, D, Temel, J S, Abernethy, A, Milanowski, J, Friend, J & Fearon, K C. (2017). ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol 28, 1949–1956.
Davenport, R J & Wright, S. (2014). Treating obesity: is it all in the gut? Drug Discov Today 19, 845–858.
Deepak, D, Furlong, N J, Wilding, J P & MacFarlane, I A. (2007). Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic–pituitary disease. Postgrad Med J 83, 277–280.
de Lind van Wijngaarden, R F, Otten, B J, Festen, D A et al. (2008). High prevalence of central adrenal insufficiency in patients with Prader-Willi syndrome. J Clin Endocr Metab 93, 1649–1654.
Dhurandhar, E J. (2016). The downfalls of BMI-focused policies. Int J Obes 40, 729–730.
Druce, M R, Wren, A M, Park, A J et al. (2005). Ghrelin increases food intake in obese as well as lean subjects. Int J Obes 29, 1130–1136.
Editorial (2017). Lancet Diabetes Endocr 5, 483.
Farholt, S, Sode-Carlsen, R, Christiansen, J S, Østergaard, J R & Høybye, C. (2011). Normal cortisol response to high-dose synacthen and insulin tolerance test in children and adults with Prader-Willi syndrome. J Clin Endocr Metab 96, E173–E180.
Farooqi, I S, Matarese, G, Lord, G M et al. (2002). Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110, 1093–1103.
Farooqi, I S, Keogh, J M, Yeo, G S H, Lank, E J, Cheetham, T & O’Rahilly, S. (2003). Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. New Eng J Med 348, 1085–1095.
Farooqi, I S, Wangensteen, T, Collins, S et al. (2007). Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. New Engl J Med 356, 237–247.
Farooqi, I S & O’Rahilly, S. (2014). Human disorders of leptin action. J Endocr 223, T63–T70.
Fasshauer, M & Blüher, M. (2015). Adipokines in health and disease. Trends Pharmacol Sci 36, 461–470.
Finan, B, Clemmensen, C & Müller, T D. (2015). Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol Cell Endocr 418, 42–54.
Fiorenza, C G, Chou, S H & Mantzoros, C S. (2011). Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocr 7, 137–150.
Frayling, T M, Timpson, N J, Weedon, M N et al. (2007). A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 316, 889–894.
Friedman, J. (2016). The long road to leptin. J Clin Invest 126, 4727–4734.
Garcia, J M. (2017). What is next after anamorelin? Curr Opin Support Palliat Care 11, 266–271.
Garcia, J M & Polvino, W J. (2007). Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist 12, 594–600.
Garcia, J M, Boccia, R V, Graham, C D et al. (2015). Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol 16, 108–116.
Gardiner, J V, Jayasena, C N & Bloom, S R. (2008). Gut hormones: a weight off your mind. J Neuroendocr 20, 834–841.
Gautier, J-F, Choukem, S-P & Girard, J. (2008). Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes & Metab 34, S65–S72.
Goldstone, A P, Holland, A J, Butler, J V & Whittington, J E. (2012). Appetite hormones and the transition to hyperphagia in children with Prader-Willi syndrome. Int J Obes 36, 1564–1570.
Goodarzi, M O. (2018). Genetics of obesity: what genetic association studies have taught us about the biology of obesity and its complications. Lancet Diabetes Endocr 6, 223–236.
Guerra, B, Fuentes, T, Delgado-Guerra, S et al. (2008). Gender dimorphism in skeletal muscle leptin receptors, serum leptin and insulin sensitivity. PLoS ONE 3, e3466.
Halawi, H, Khemani, D, Eckert, D et al. (2017). Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial. Lancet Gastro Hepatol 2, 890–899.
Harz, K J, Müller, H L, Waldeck, E, Pudel, V & Roth, C. (2003). Obesity in patients with craniopharyngioma: assessment of food intake and movement counts indicating physical activity. J Clin Endocr Metab 88, 5227–5231.
Haqq, A M, Farooqi, I S, O’Rahilly, S et al. (2003). Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi Syndrome. J Clin Endocr Metab 88, 174–178.
Hay, D L, Chen, S, Lutz, T A, Parkes, D G & Roth, J D. (2015). Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev 67, 564–600.
Henderson, D C, Vincenzi, B, Andrea, N V, Ulloa, M & Copeland, P M. (2015). Pathophysiological mechanisms of increased cardiometabolic risk in people with schizophrenia and other severe mental illnesses. Lancet Psychiat 2, 452–464.
Heymsfield, S B & Wadden, T A. (2017). Mechanisms, pathophysiology, and management of obesity. New Eng J Med 376, 254–266.
Heymsfield, S B, Greenburg, A S, Fujioka, K et al. (1999). Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282, 1568–1575.
Hosojima, H, Togo, T, Odawara, T et al. (2006). Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol 20, 75–79.
Hotta, M, Ohwada, R, Akamizu, T, Shibasaki, T & Kangawa, K. (2012). Therapeutic potential of ghrelin in restricting-type anorexia nervosa. Methods Enzymol 514, 381–398.
Igaki, N, Tanaka, M & Goto, T. (2005). Markedly improved glycemic control and enhanced insulin sensitivity in a patient with type 2 diabetes complicated by a suprasellar tumor treated with pioglitazone and metformin. Intern Med 44, 832–837.
Inge, T H, Pfluger, P, Zeller, M et al. (2007). Gastric bypass surgery for treatment of hypothalamic obesity after craniopharyngioma therapy. Nat Clin Pract Endocr Metab 3, 606–609.
Irizarry, K A, Miller, M, Freemark, M & Haqq, A M. (2016). Prader Willi syndrome: genetics, metabolomics, hormonal function, and new approaches to therapy. Adv Ped 63, 47–77.
Ismail, D, O’Connell, M A & Zacharin, M R. (2006). Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Ped Endocr Metab 19, 129–134.
Karra, E, O’Daly, O G, Choudhury, A I et al. (2013). A link between FTO, ghrelin, and impaired brain food-cue responsivity. J Clin Invest 123, 3539–3551.
Kleinert, M, Clemmensen, C, Stemmer, K, Müller, T D, DiMarchi, R D & Tschöp, M H. (2017). Emerging poly-agonists for obesity and type 2 diabetes. Obesity 25, 1647–1649.
Krude, H, Biebermann, H, Luck, W, Horn, R, Brabant, G & Grüters, A. (1998). Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Gen 19, 155–157.
Krude, H & Grüters, A. (2000). Implications of pro-opiomelanocortin (POMC) mutations in humans: the POMC deficiency syndrome. Trends Endocr Metab 11, 15–22.
Kühnen, P, Clément, K, Wiegand, S et al. (2016). Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. New Eng J Med 375, 240–246.
Kyriakidis, M, Caetano, L, Anastasiadou, N, Karasu, T & Lashen, H. (2016). Functional hypothalamic amenorrhoea: leptin treatment, dietary intervention and counselling as alternatives to traditional practice – systematic review. Europ J Obstet Gynecol Reprod Biol 198, 131–137.
Licinio, J, Caglayan, S, Ozata, M et al. (2004). Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 101, 4531–4536.
Lippl, F, Erdmann, J, Steiger, A et al. (2012). Low-dose ghrelin infusion – evidence against a hormonal role in food intake. Regul Peptides 174, 26–31.
Locke, A E, Kahali, B, Berndt, S et al. (2015). Genetic studies of body mass index yield new insights for obesity biology. Nature 518, 197–206.
Loos, R J F & Yeo, G S H. (2014). The bigger picture of FTO – the first GWAS-identified obesity gene. Nat Revs Endocr 10, 51–61.
Lu, M L, Wang, T N, Lin, T Y et al. (2015). Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 58, 47–50.
Maffetone, P B, Rivera-Dominguez, I & Laursen, P B. (2017). Overfat adults and children in developed countries: the public heath importance of identifying excess body fat. Front public health 5, Article # 190.
Mancini, M C & de Melo, M E. (2017). The burden of obesity in the current world and the new treatments available: focus on liraglutide 3.0 mg. Diabetol Metab Syndrom 9, 44.
Mendiratta, M S, Yang, Y, Balazs, A E et al. (2011). Early onset obesity and adrenal insufficiency associated with a homozygous POMC mutation. Int J Ped Endocr 2011: 5.
Messidoro, C, Elte, J W F, Cabezas, M C, van Agteren, M, Lacroix, A & de Herder, W W. (2009). Food-dependent Cushing’s syndrome. Netherlands J Med 67, 187–190.
Morton, G M, Meek, T H & Schwartz, M W. (2014). Neurobiology of food intake in health and disease. Nat Revs Neurosci 15, 367–378.
Müller, T D, Tschöp, M H & O’Rahilly, S. (2016). Metabolic precision medicines: curing POMC deficiency. Cell Metab 24, 194–195.
Musso, C, Cochran, E, Javor, E, Young, J, DePaoli, A M & Gorden, P. (2005). The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients. Metab Clin Exp 54, 255–263.
Myers, M G, Jr., Leibel, R L, Seeley, R J & Schwartz, M W. (2010). Obesity and leptin resistance: distinguishing cause from effect. Trends Endocr Metab 21, 643–651.
NCD Risk Factor Collaboration (NCD-RisC). (2017). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet 390, 2627–2642.
Ozsu, E, Ceylaner, S & Onay, H. (2017). Early-onset severe obesity due to complete deletion of the leptin gene in a boy. J Ped Endocr Metab 30, 1227–1230.
Paz-Filho, G, Mastronardi, C A & Licinio, J. (2015). Leptin treatment: facts and expectations. Metab Clin Exp 64, 146–156.
Pigeyre, M, Yazdi, F T, Kaur, Y & Meyre, D. (2016). Recent progress in genetics, epigenetics and metagenomics unveils the pathophysiology of human obesity. Clin Sci 130, 943–986.
Pi-Sunyer, X, Astrup, A, Fujioka, K et al. (2015). A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New Engl J Med 373, 11–22.
Ravussin, E, Smith, S R, Mitchell, J A et al. (2009). Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy. Obesity 17, 1736–1743.
Rehfeld, J F. (2017). The changing concept of gut endocrinology. Endocr Develop 32, 8–19.
Reitman, M L. (2016). Hormone-replacement therapy for melanocyte-stimulating hormone deficiency. New Eng J Med 375, 278–279.
Rhea, E M, Salameh, T S, Logsdon, A F, Hanson, A J, Erickson, M A & Banks, W A. (2017). Blood-brain barriers in obesity. AAPS 19, 921–930.
Roth, C L, Eslamy, H, Werny, D et al. (2015). Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity. Obesity 23, 1226–1233.
Sahin-Efe, A, Upadhyay, J, Ko, B-J et al. (2017). Irisin and leptin concentrations in relation to obesity, and developing type 2 diabetes: a cross sectional and a prospective case-control study nested in the normative aging study. Metab 79, 24–32.
Schorr, M & Miller, K K. (2017). The endocrine manifestations of anorexia nervosa: mechanisms and management. Nat Revs Endocr 13, 174–186.
Schultes, B, Ernst, B, Schmid, F & Thurnheer, M. (2009). Distal gastric bypass surgery for the treatment of hypothalamic obesity after childhood craniopharyngioma. Eur J Endocr 161, 201–206.
Schwartz, M W & Morton, G J. (2002). Obesity: keeping hunger at bay. Nature 418, 595–597.
Schwartz, M W, Seeley, R J, Zeltser, L M et al. (2017). Obesity pathogenesis: An endocrine society scientific statement. Endocr Revs 38, 267–296.
Scuteri, A, Sanna, S, Chen, W-M et al. (2007). Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet 3, e115.
Speakman, J R. (2015). The ‘Fat Mass and Obesity Related’ (FTO) gene: mechanisms of impact on obesity and energy balance. Curr Obes Rep 4, 73–91.
Spiegel, K, Tasali, E, Leproult, R, Scherberg, N & Van Cauter, E. (2011). Twenty-four-hour profiles of acylated and total ghrelin: relationship with glucose levels and impact of time of day and sleep. J Clin Endocr Metab 96, 486–493.
Steinert, R E, Feinle-Bisset, C, Asarian, L, Horowitz, M, Beglinger, C & Geary, N. (2017). Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB. Physiol Rev 97, 411–463.
Stunkard, A J, Harris, J R, Pedersen, N L & McClearn, G E. (1990). The body mass index of twins who have been reared apart. N Engl J Med 322, 1483–1487.
Tam, C S, Lecoultre, V & Ravussin, E. (2011). Novel strategy for the use of leptin for obesity therapy. Expert Opin Biol Ther 11, 1677–1685.
Tan, T, Behary, P, Tharakan, G et al. (2017). The effect of a subcutaneous infusion of GLP-1, OXM, and PYY on energy intake and expenditure in obese volunteers. J Clin Endocr Metab 102, 2364–2372.
The GBD Obesity Collaborators (2017). Health effects of overweight and obesity in 195 countries over 25 years. New Eng J Med 377, 13–27.
Thondam, S K, Cuthbertson, D J, Aditya, B S, MacFarlane, I A, Wilding, J P & Daousi, C. (2012). A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus. Clin Endocr 77, 635–637.
Tomiyama, A J, Hunger, J M, Nguyen-Cuu, J & Wells, C. (2016). Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005–2012. Int J Obes 40, 883–886.
Tschöp, M, Weyer, C, Tataranni, P A, Devanarayan, V, Ravussin, E & Heiman, M L. (2001). Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709.
Tschöp, M H, Finan, B, Clemmensen, C et al. (2016). Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24, 51–62.
Tung, Y C L, Yeo, G S H, O’Rahilly, S & Coll, A P. (2014). Obesity and FTO: changing focus at a complex locus. Cell Metab 20, 710–718.
Uher, R & Treasure, J. (2005). Brain lesions and eating disorders. J Neurol Neurosurg Psych 76, 852–857.
Valette, M, Bellisle, F, Carette, C et al. (2013). Eating behaviour in obese patients with melanocortin-4 receptor mutations: a literature review. Int J Obes 37, 1027–1035.
Valette, M, Poitou, C, Kesse-Guyot, E et al. (2014). Association between melanocortin-4 receptor mutations and eating behaviors in obese patients: a case–control study. Int J Obes 38, 883–885.
Wabitsch, M, Funcke, J-B, Lennerz, B et al. (2015). Biologically inactive leptin and early-onset extreme obesity. New Engl J Med 372, 48–54.
World Obesity Federation (2017). Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Revs 18, 715–723.
Yang, Q, Xiao, T, Guo, J & Su, Z. (2017). Complex relationship between obesity and the fat mass and obesity locus. Int J Biol Sci 13, 615–629.
Yeo, G S H. (2017). Genetics of obesity: can an old dog teach us new tricks? Diabetologia 60, 778–783.
Yi, X, Yuan, D, Farr, S A, Banks, W A, Poon, C-D & Kabanov, A V. (2014). Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity. J Control Release 191, 34–46.
Zelissen, P M J, Stenlof, K, Lean, M E J, Fogteloo, J, Keulen, E T P, Wilding, J. (2005). Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes Obes Metab 7, 755–761.